ReviewCurrent oncology reports2003
The role of epidermal growth factor receptor in head and neck squamous cell carcinoma.
Review in Current oncology reports, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 64 citations in OpenAlex.
- Insights into metastatic roadmap of head and neck cancer squamous cell carcinoma based on clinical, histopathological and molecular profiles.Molecular biology reports · 2024Review
- First Clinical Results of Fluorescence Lifetime-enhanced Tumor Imaging Using Receptor-targeted Fluorescent Probes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Exposure to chewing tobacco promotes primary oral squamous cell carcinoma and regional lymph node metastasis by alterations of SDF1α/CXCR4 axis.International journal of experimental pathology · 2021Article
- Precision Therapy of Head and Neck Squamous Cell Carcinoma.Journal of dental research · 2018Review
- Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment.Cancers · 2017Review
- The prognostic value of Tiam1 protein expression in head and neck squamous cell carcinoma: a retrospective study.Chinese journal of cancer · 2015Article
- Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.Molecular imaging and biology · 2013Article
- Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma.BMC cancer · 2012Article
- Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.The American journal of pathology · 2011Article
- High SEPT9_v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell Carcinoma.Translational oncology · 2010Article
- ErbB receptors in the biology and pathology of the aerodigestive tract.Experimental cell research · 2009Review
- Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
- Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model.Head & neck · 2008Article
- A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.Cancer research · 2008Article
- Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.British journal of cancer · 2006Article
- Novel management of oral cancer: a paradigm of predictive oncology.Clinical medicine & research · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth factor receptors play a crucial role in the cell proliferation pathways involved in the development of cancer. One such receptor, the epidermal growth factor receptor (EGFR), is upregulated in many types of human tumors, particularly head and neck squamous cell carcinoma (HNSCC). EGFR overexpression in HNSCC has been the basis for investigation of therapeutic strategies that target EGFR. EGFR-blocking methods under evaluation involve immunotoxins, monoclonal antibodies, EGFR-specific tyrosine kinase inhibitors, and antisense approaches. These molecular targeting tactics have produced a number of agents that are currently in various stages of preclinical investigation, along with clinical trials to assess their potential as anticancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.